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Abstract
Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead
compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity. They are
of particular importance for novel, first-in-class mechanisms, where the ability of a targeted therapeutic to impact disease
outcome is often unknown. By definition, proximal PD biomarkers aim to measure the interaction of a drug with its
biological target. For kinase drug discovery, protein substrate phosphorylation sites represent candidate PD biomarkers.
However, substrate phosphorylation is often controlled by input from multiple converging pathways complicating
assessment of how potently a small molecule drug hits its target based on substrate phoshorylation measurements alone.
Here, we report the use of quantitative, differential mass-spectrometry to identify and monitor novel drug-regulated
phosphorylation sites on target kinases. Autophosphorylation sites constitute clinically validated biomarkers for select
protein tyrosine kinase inhibitors. The present study extends this principle to phosphorylation sites in serine/threonine
kinases looking beyond the T-loop autophosphorylation site. Specifically, for the 39-phosphoinositide-dependent protein
kinase 1 (PDK1), two phospho-residues p-PDK1
Ser410 and p-PDK1
Thr513 are modulated by small-molecule PDK1 inhibitors,
and their degree of dephosphorylation correlates with inhibitor potency. We note that classical, ATP-competitive PDK1
inhibitors do not modulate PDK1 T-loop phosphorylation (p-PDK1
Ser241), highlighting the value of an unbiased approach to
identify drug target-regulated phosphorylation sites as these are complementary to pathway PD biomarkers. Finally, we
extend our analysis to another protein Ser/Thr kinase, highlighting a broader utility of our approach for identification of
kinase drug-target engagement biomarkers.
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Introduction
Drug development remains an expensive, uncertain and
challenging endeavor. The cost from discovery to regulatory
approval of a novel drug averages about $900 million out of
pocket, with a capitalized cost of ,$1.78 billion, and the process
now typically takes up towards 13 years [1–3]. Moreover, on
average nine out of ten drugs entering clinical development do not
receive marketing approval and projects often fail to provide
proof-of-concept for efficacy (Ph II) or in late development (Phase
III) adding a high degree of risk to drug development [1,2].
Consequently, the pharmaceutical industry is looking for ways to
improve the probability of success for each drug development
candidate by selecting not only the best compounds, but also drug-
specific biomarkers to precisely measure the level of target
inhibition and identify the patients likely to benefit from the drug
as early as possible [4]. In fact, the incorporation of biomarkers
early in the drug discovery process has become of such importance
that it informs ‘go/no-go’ decisions on moving drug candidates
forward towards the clinic [5–10].
Biomarkers are defined as molecular entities that can be
measured and evaluated objectively as indicators of normal
biological processes, pathogenic processes or pharmacological
response to therapeutics and can be categorized as either proximal
(target-related) or distal (disease-related) [11,12]. Some of the
guiding principles underlying biomarker-driven drug discovery
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sequential questions: Are there active concentrations of drug in plasma,
blood and tissue? Is the target engaged? Is there downstream pathway
inhibition? Is there a biological effect or clinical response? [10]. While
pharmacokinetic (PK) measurements of drug concentrations in
plasma are routine, establishing whether a drug interacts with its
molecular target (i.e. inhibition/activation) sufficiently to obtain a
biological response has proven to be a challenging endeavor.
For kinase drug discovery, phosphorylated protein substrates of
a kinase drug target represent attractive PD biomarker candidates.
However, an inverse linear relationship between the stoicheometry
of substrate phosphorylation and the degree of kinase inhibition
seldom exists as the phosphorylation state of a given protein
usually depends on convergent upstream input from multiple
signaling pathways as well as negative and positive feedback loop
regulation. Moreover, the phosphorylation of a particular sub-
strate site is subject to variable rates of turnover depending on the
dedicated phosphatase activity against said phosphorylation site.
Despite these limitations, if a drug with a novel unproven
mechanism fails to achieve the desired clinical activity, evaluation
of PD biomarkers, when available, is an important means to assess
the degree of target engagement by the drug. If the PD biomarkers
indicate strong target engagement, the lack of clinical activity is
likely due to the biology/mechanism of the target. Conversely,
minimal target engagement due to non-favorable properties of the
molecule or insufficient dosing will dictate additional pharmaco-
logical activities to address these issues.
For protein kinases, amino acid sequence alignments combined
with site-directed mutagenesis and enzymatic assay have revealed
conserved regulatory phosphorylation sites [13,14]. For many
kinases, a direct relationship between the phosphorylation state of
such regulatory residues and their catalytic activity has been
established [15]. Hence, monitoring the phosphorylation status of
the activation site in kinase drug targets is a direct means of
assessing drug-mediated kinase inhibition, and hence it serves as a
direct PD biomarker. Specifically, for protein tyrosine kinases,
monitoring the inhibition of kinase T-loop phosphorylation has
been used to support the clinical development of a number of
small-molecule inhibitors targeting EGFR, HER2 and cMET [16–
18]. So far, this approach has been limited to a few protein
tyrosine kinases with well-characterized autophosphorylation sites.
Although activation of phosphorylation of Ser/Thr protein kinases
is well studied in phosphorylation dependent signaling, it is also
more complex, and subject to a multitude of allosteric regulatory
mechanisms, via cis or trans- activation [19–21] rendering this
approach challenging at best for this class of drug targets .
In order to assess kinase drug-target engagement independent of
prior knowledge of kinase (auto)phosphorylation sites, such as the
conserved T-loop phosphorylation site, we here report a broadly
applicable, quantitative, differential mass spectrometric (MS)
approach for identification and quantification of all direct and
indirect drug-regulated phosphorylation sites in any kinase drug
target.
We recently characterized a panel of structurally diverse PDK1-
targeted lead compounds that inhibit the phosphorylation of
PDK1 substrates such as AKT
Thr308 and p90RSK
Ser221 in
multiple cell lines [22]. In that study, we also reported that
treatment of cells with classical, ATP-competitive PDK1 kinase
inhibitors do not result in decreased PDK1 T-loop autophospho-
rylation levels eliminating this phosphorylation site (p-PDK1
Ser241)
as a candidate target engagement biomarker for PDK1 inhibitor
development. While it is informative to monitor the inhibition of
proximal PD biomarkers (i.e. p-AKT
Thr308 and p-p90RSK
Ser221)
in response to PDK1 inhibitor treatment, it is well established that
the phosphorylation state of AKT is regulated indirectly by many
other protein kinases including a majority of receptor protein
tyrosine kinases, as well as lipid kinases, most notably phospho-
inositide 39-kinase (PI39K). Accordingly, the observation that a
PDK1-targeted small molecule inhibitor modulates p-AKT
Thr308
does not guarantee that this is due to direct inhibition of PDK1,
despite PDK1 is the upstream activating kinase of AKT that
directly phosphorylates the T-loop phosphorylation site Thr308 in
AKT. Based on these facts, we set out to identify drug-regulated
phosphorylation sites on PDK1 that could be used to link direct
PDK1 drug-target engagement in cells to biological responses.
Specifically, we mapped and quantified 12 serine/threonine
phosphorylation sites on PDK1, including novel phosphorylation
sites, and found that two of these sites, p-PDK1
Ser410 and p-
PDK1
Thr513, were modulated by pharmacological inhibitors of
PDK1. Moreover, the degree of dephosphorylation of these sites
correlated with the inhibitor potency (IC50) in PDK1 enzymatic
assays.
Results
The catalytic activity of protein kinases is tightly controlled by
reversible protein phosphorylation [23,24]. Protein autophospho-
rylation operates through a cis inhibition/trans activation mecha-
nism and phosphorylation changes exerted by upstream kinases or
phosphatases regulate kinase catalytic activity through allosteric
conformational changes [18,25,26]. Under normal physiological
conditions where kinase activity is tightly controlled, a unifying
mechanism for oncogenic conversion, whether through point
mutations, fusion events, or amplifications, is the relief of
autoinhibitory constraints usually reflected in enhanced autophos-
phorylation [22]. Accordingly, drug-mediated inhibition of such
(auto)phosphorylation sites provides a direct means for assessing
kinase drug target engagement and inhibition as it often reports on
the enzymatic activity of the kinase in cells (Figure 1A). Recent
mass spectrometric studies have identified a vast number of novel
protein phosphorylation sites in the human kinome as illustrated
by the phosphorylation map for PDK1 (Figure 1B) [27–29].
However, regulatory functions for most identified phosphorylation
sites remain poorly understood.
We have recently characterized a panel of structurally diverse
PDK1 inhibitors and found that classical, ATP-competitive
inhibitors do not inhibit the PDK1 T-Loop phosphorylation site
(Ser241) in PC3 cells, yet inhibit bona fide PDK1 substrates such as
p-AKT
Thr308 and p-RSK
Ser221 [22] as shown in Figure 2A.
Accordingly, to support the lead optimization of selective small-
molecule PDK1 inhibitors, we established a LuminexH bead-based
assay to measure p-AKT
Thr308 inhibition in cells in response to
inhibitor treatment (Figure 2B). The PTEN-deficient prostate
cancer cell line LNCap was selected as a model system because of
its high basal phosphorylation state of AKT and a robust assay
performance using commercially available reference inhibitors of
PI3K and AKT (data not shown). In parallel, an ‘in-cell’ western
blotting assay was established [30] to measure the cellular
inhibition of p-RSK
Ser221 in PC3 cells (Figure 2C). In total, more
than 400 compounds were tested in these assays and the cellular
potency of compounds was correlated with their intrinsic activity
against recombinant, purified PDK1 enzyme (Figure 2B & C)
using the previously described enzymatic assays [30,31]. In
contrast to the observed correlation between the inhibitory
potency against PDK1 enzymatic activity (IC50) and the cellular
inhibition of p-RSK
Ser221 in PC3 cells (Figure 2B), when small-
molecule PDK1 inhibitors were tested in LNCap cells, the
enzymatic potency of inhibitors against PDK1 did not correlate
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Thr308 (Figure 2C). This is
surprising, as p-AKT
Thr308 is effectively inhibited in PC3 cells
using a highly selective (.1000-fold) PDK1 inhibitor [22] and
genetic knock-out of PDK1 completely abolishes the phosphory-
lation of AKT
Thr308 in mouse embryonic fibroblasts (MEFs) [32].
Notably, kinase selectivity profiling of representative compounds
showed that the inhibition of p-AKT
Thr308 correlated with lack of
kinome selectivity (Figure 2D). Thus, we conclude that the
compound-mediated inhibition of p-AKT
Thr308 in LNCap is
likely due to off-target activities of these molecules, including
targeting either the PI3K/PDK1/AKT pathway, receptor tyro-
sine kinases (RTKs) and/or lipid kinases such as PI39K. Indeed,
side-by-side comparison of PDK1-inhibitor-treated PC3 and
LNCap cells confirmed that p-AKT
Thr308 is not a universal PD
biomarker for PDK1 kinase inhibitor development whereas p-
RSK
Ser211 appears to be consistently inhibited across cell lines
(Figure 2E). The observation that PDK1 activity does not appear
to be rate-limiting for phosphorylation of AKT
Thr308 in LNCap
cells would be consistent with the extensive pathway cross talk and
compensatory mechanisms (e.g. negative/positive stimuli and
feedback loops) that have been reported for the PI3K-pathway
(Figure 2F). Our observation also supports recent genetic PDK1
knock-down studies in PTEN deficient mouse tumor models
showing only marginal effects on Thr308 phosphorylation [33].
Consequently, because inhibition of p-AKT
Thr308 does not directly
correlate with the degree of PDK1 target inhibition in cells we set
out to identify novel drug-regulated phosphorylation sites on
PDK1 as potential candidates for direct read-out of drug-target
engagement and inhibition of PDK1.
In a more unbiased effort to delineate the effects of ATP-
competitive PDK1 inhibitors on the kinase itself, we performed
quantitative SILAC mass spectrometric (MS) phosphorylation site
analysis on immunoprecipitated PDK1 from cells treated with 4
structurally diverse PDK1 inhibitors for 24 hrs according to the
workflow shown in Figure 3. The change of a particular
phosphorylation site of interest was derived by comparing the
signal intensity of the isotopically labeled ‘‘heavy’’ and radioiso-
tope neutral ‘‘light’’ peptide pair, which was further normalized
against a vehicle-to-vehicle control [34]. While desirable, we were
unsuccessful at immunopurifying endogenous PDK1 protein from
cells in sufficient quantities for subsequent MS analysis. Therefore,
we over expressed MYC-tagged PDK1 in 293T cells as further
described in Materials and Methods. We, subsequently, immuno-
purified PDK1 from cells that were drug treated (grown in ‘heavy’
isotope-labeled media), and DMSO treated (grown in ‘light’
media) (Figures 4A & 4B). In-gel proteolytic digestion coupled with
mass spectrometric analysis identified 12 phosphorylation sites
with ,95% sequence coverage of full length PDK1 (Figure 4C).
Interestingly, amongst these, three phosphorylated peptides which
harbor the PDK1 amino acid residues Ser410 and Thr513 showed
Figure 1. Large scale phosphorylation analyses add an unprecedented layer of information to kinases. A) Regulation of enzyme activity
by reversible protein phosphorylation. Because the phosphorylation state of kinases often correlates with enzymatic activity, monitoring site-specific
phosphorylation events are attractive biomarkers for measuring drug-target inhibition. B) Previously reported phosphorylation sites on PDK1.
doi:10.1371/journal.pone.0026459.g001
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Ser241 is not
modulated by PDK1 inhibitor treatment in PC3 cells whereas downstream substrates, such as p-AKT
Thr308 and p-RSK
Ser221, are affected. B) In PC3 cells
the inhibition of p-RSK
Ser221 correlates with the enzymatic potency of PDK1 inhibitors (N=147). C) LNCap cells don’t exhibit a correlation between
inhibition of p-AKT
Thr308,abona fide PDK1 substrate (N=279), and the D) enzymatic potency of PDK1 inhibitors (N=82). E) Western blot of p-
AKT
Thr308 and p-RSK
Ser221 in a variety of cell lines. F) PDK1 substrates are subject to feedback regulation and pathway cross-talk.
doi:10.1371/journal.pone.0026459.g002
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with the four structurally diverse ATP-competitive PDK1
inhibitors compared to vehicle control (Figure 4D). In contrast,
peptides containing phosphorylated Ser241 were not modulated
under any of the treatment conditions tested, consistent with
Western blotting analysis (Figure 4D and data not shown).
Notably, two distinct phosphopeptides harboring pPDK1
Ser410
exhibited the same reduction in phosphorylation by each of the
small molecule inhibitors (Figure 4D). The corresponding MS/MS
spectra for p-Ser241 (ANpSFVGTAQYVSPELLTEK), p-Ser410
(DTGLPQRSGpSNIEQYIH), and p-Thr513 (NFKpTFFVH-
TPNR) are shown in Figure 4E. These results support the use of
immunoaffinity precipitation (IAP–MS) to identify and quantify
drug-specific phosphorylation changes as a means to measure drug
target engagement in cells.
Discussion
The human genome encodes a little more than 500 protein
kinases and an estimated twenty percent of drugs currently in
development target this enzyme class [24]. To successfully identify,
develop, and utilize biomarkers for novel drug targets a question-
based pharmacological audit-trail has been proposed [35,10]. The
answers are provided by fit-for-purpose biomarkers gating the
development of the molecule (Figure 5). Arguably, target
engagement and downstream PD markers are to be incorporated
early on in the process as they collectively inform on biochemical
target modulation with consequent downstream pathway effects.
With an in depth understanding of drug efficacy in terms of target
engagement, pharmacokinetic and pharmodynamic (PK-PD)
relationships can be established in preclinical animal models and
ultimately inform on both drug dose and schedule in human
clinical studies.
Examples already exist for RTK inhibitors where inhibition of
T-loop autophosphorylation of the drug target provides a direct
readout for the degree of drug target inhibition. For example,
Dasatinib is a multi-targeted inhibitor of BCR-Abl and SRC
family kinases, which has clinical activity in CML. Modulation of
BCR-ABL phosphorylation in combination with phosphorylation
of its downstream substrate CRKL has been successfully used to
inform clinical decision-making [36]. Following a single oral
administration of Dasatinib at preclinical efficacious doses,
mathematical modeling of PK-PD relationships was used to
predict the human plasma concentration needed to achieve 90%
target inhibition (IC90) [36]. If these results are applicable to kinase
targets in general, drug-specific phosphorylation modulations of
the kinase itself can provide for direct target engagement markers.
When complemented with knowledge of drug plasma and/or
tissue concentration, desired biological effects, such as cell cycle
arrest or apoptosis in cancer cells, can be used as evidence for the
molecular interaction of the drug with the target in vivo and hence
inform about true drug target exposure. Such combined
information has far-reaching potential, and can provide evidence
whether a molecule fails clinical proof-of-concept (POC) for
efficacy in clinical trials due to the biological mechanism or simply
due to lack of target modulation. It is important to emphasize that
target engagement biomarkers, while defining the molecular
effects of the drug on the purported target, may not necessarily
have any correlation with the desired clinical effects (Figure 5).
Knowledge about good drug target exposure yet no desirable
clinical or biochemical efficacy might warrant further investigation
into the biological role of the target in disease biology
In this study, we present a quantitative phosphoproteomics
based approach to discover direct target engagement biomarkers
for Ser/Thr protein kinase drug discovery focusing on the PI39K
pathway target PDK1 as an example (Figure 2). The discovery of
novel drug-regulated phosphorylation sites on this target produces
evidence directly correlating the target engagement/PD biomark-
er to the pathway inhibition (Figure 4). We identified p-Ser410
and p-Thr513 to be regulated by classical, type I ATP competitive
PDK1 inhibitors in a dose-dependent correlation, while p-Ser241
was not modulated at all. Very limited information exists for the
regulatory effect of these phosphorylation sites on PDK1 activity
with only 2 reports to date discussing the importance of p-Ser410
[27] and of p-Thr513 [37] phosphorylation for the PDK1 enzyme
activity.
To demonstrate that the herein described approach is more
universally applicable (Figure 3) we employed the same strategy to
identify drug-regulated target engagement phosphorylation mark-
ers for two additional protein kinases, the serine/threonine protein
kinase MARK3 as well as a RTK, c-Met. We found that
transiently transfected MARK3 exhibited substantial phosphory-
lation on 22 sites based on our proteomics analysis, with ,95% of
sequence coverage (Figure S1). Amongst these 22 phosphorylation
sites, 17 had signal intensities that were quantifiable with nine
phosphorylation sites reproducibly decreased by two structurally
diverse inhibitors of MARK3 (Figure S1). Specifically, signal
intensities of peptides containing phosphorylation at Ser390/391,
Ser400, and Ser469 showed a dose-dependent decrease in
response to both compounds. In contrast, p-Ser19, p-Ser598/
601 and p-Ser583/587 were strongly inhibited by only one of the
compounds. Similarly, the herein described methodology has
proven equally successful for RTKs [16]. Differential mass-
spectrometry of endogenously immunoprecipitated c-Met from
Figure 3. Schematic of stable isotope labeling with amino acid
in cell culture and immuno-affinity precipitation for MS
analysis (SILAC-IAP-MS). T293 cells grown in either light (
12C-Arg,
12C-Lys) or heavy (
13C-Arg,
13C-Lys) medium were lysed and combined
at a 1:1 ratio based on total protein quantity. PDK1 was immunopre-
cipitated and analyzed by mass spectrometry. MS raw data were
quantified by the Elucidator software 3.5 and confirmed by manual
validation as described in the Materials and Methods.
doi:10.1371/journal.pone.0026459.g003
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inhibitor, strongly modulates not only the T-loop activation loop
(Y1230/Y1234/Y1235), but also phosphorylation sites that are
within the COOH-terminal docking site (Y1349 and Y1365)
(Figure S2 and Table S1). These examples demonstrate that our
proposed method will enable differentiation of small molecules
developed against the same targets. The variable effects of these
drugs on the target are likely due to different binding
characteristics and/or binding sites, resulting in different allosteric
conformations with variable effects on kinase autophosphory-
lation. Another reason could be different off-target -effects
resulting in variable indirect effects on target phosphorylation
due to the complex network of interactions inside a cell.
A key question is how such novel drug target engagement-
regulated phosphorylation sites can be translated into clinical,
practical usage. The answer to this question depends in part where
to measure and what analytical assays are to be employed. The
strength of the herein laid out approach is to broadly identify and
quantify effects of molecules on the phosphorylation status without
a priori knowledge. However, we note that the identification of
candidate target engagement markers is performed in vitro, and
importance is initially inferred from corresponding potency data.
The answer to the question ‘which phosphorylation sites are
modulated in vivo’ requires access actual diseased human tissue and
appropriate tools. We and others are advocating a pre and post-
dose biopsy driven trial design in where pathway and target
modulation is directly assessed in the target tissue of interest [5,38].
In cases where specific antibody reagents are available, biochem-
ical and/or immunohistochemical (IHC) assays can be established
for use in the clinic, or if needed, phosphorylation specific
antibodies must be generated. However, as this study has
illustrated, many of the drug-regulated sites are either novel, and
Figure 4. Relative quantification of hPDK1 phosphorylation from 293T cells treated with ATP competitive PDK1 inhibitors using
SILAC-IAP-MS. A) SDS-PAGE and isolation of the PDK1 protein band for LC-MS/MS analysis. B) PDK1 tool compounds representing three
structurally distinct chemical classes. PDK1 enzymatic activity is shown (EC50). C) Mapping of phosphorylation sites of immunoprecipitated PDK1 from
293T cells identifies 12 Ser/Thr phosphorylation sites with ,95% sequence coverage. D) Relative quantification by SILAC-IAP-MS showed a greater
than 4 fold reduction of two phosphorylation sites (pS410, and pT513) in samples treated with PDK1 inhibitors compared to samples treated with
DMSO. In contrast, no change in phosphorylation was detected in the self-to-self control sample where 293T cells grown in heavy and light media
were both treated with DMSO prior to mixing. E) MS/MS spectra for pS241 (ANpSFVGTAQYVSPELLTEK), pS410 (DTGLPQRSGpSNIEQYIH), and pT513
(NFKpTFFVHTPNR) containing peptides.
doi:10.1371/journal.pone.0026459.g004
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spectrometry is at the core of the described approach and essential
for the discovery of these biomarkers, it is plausible that the future
development of highly sensitive, robust, selective, and absolute
quantitative MS based assays could become an attractive
alternative approach when antibody reagents are not available
or not easily generated [39–42]. While conceptionally straightfor-
ward, significant improvements of phospho-MS based assays, in
the form of increasing sensitivity in MS instrumentations and
robustness of biochemical isolation from minute amounts of
clinical materials, are yet to be realized.
Methods
Materials
LNCap, PC3, and 293FT cells were purchased from American
Tissue Type Collection. All antibodies were used at a concentra-
tion of 1:1000 and purchased from Cell Signaling Technology,
Inc. Metablolic SILAC labeling kits were purchased from
Invitrogen. All other reagents were purchased from their
respective manufactures as described below.
Cell culture and SILAC labeling
T293 cells were grown for seven passages in DMEM media
containing either normal-isotope lysine, arginine (‘light medium’)
or
13C6 containing lysine and arginine (‘heavy medium’) in high
glucose, L-glutamine, 110 mg/L sodium pyruvate and 10% FBS.
Myc-tag PDK1 (pCMV5-PDK1-wt) was transiently transfected
into 293FT cells (5610
6 cells per 10 cm petri dish) using standard
293FT LV packaging transfection protocols (i.e. lipofectamine in
OPTI-MEM). Kinase inhibitors or control (DMSO) were added
18 hours prior to cell lysis using immunoprecipitation buffer
(50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM
EDTA, protease inhibitor tablet (Roche), 1 mM b-Glycerolpho-
sphate, 1 mM Na3VO4, 2.5 mM Sodium pyrophosphate). ‘Heavy’
and ‘light’ isotope-labeled samples were mixed 1:1 based on the
protein concentration measurement using standard BCA protocol.
250 ml lysate was pre-cleared by adding 30 ml of a 50% Protein-A
agarose slurry for ,2 hours and PDK1 was immunoprecipitated
via tag-specific pull down (anti-c-MYC antibody) and subjected to
SDS-PAGE and stained with Coomassie blue. The identical
procedure was also carried out for a 1;1 mix of cells grown in
‘heavy’ and ‘light’ isotope without compound treatment as an
internal control.
Western Blot analysis
Western blotting was performed for 2 h using a BioRad
SemiDry apparatus with Immobilon-P PVDF membrane (Milli-
pore), at a constant voltage of 25 V and 10A/10 cm2. Chemilu-
minescent detection was carried out using CDP Star
TM (Tropix,
Bedford, MA, USA) per recommendations by the manufacturer.
Luminex and In-Cell assays for p90RSK
Ser221 and
pAKT
Thr308
Development of biochemical assays to report on phospho-
p90RSK
Ser221 and phospho-AKT
Thr308 were previously reported
and performed as described [30,31].
Biochemical processing and mass spectrometry
Excised protein bands were reduced, alkylated and digested
with Trypsin (Promega), GluC (Roche) and AspN (Roche)
overnight at the room temperature. The resulting peptides were
analyzed by a reverse-phase nano-liquid chromatography system
(1100 Series HPLC system; Agilent Technologies) online-coupled
with a LTQ Orbitrap hybrid mass spectrometer with electron
transfer dissociation (LTQ Orbitrap XL ETD) (ThermoFisher
Scientific). Briefly, an aliquot of the digested sample was loaded
onto a micro-capillary liquid chromatography column (50 mm
i.d.625 cm packed with Magic C18). Bound peptides were eluted
from the column via a 75 min solvent gradient program. Eluted
peptides were continuously converted to multiply charged peptide
ions by electrospray ionization and introduced into the vacuum
system of a LTQ Orbitrap XL ETD. High resolution mass spectra
were acquired at a rate of 1 spectrum per second. These spectra
recorded the intensity, retention time, and accurate mass-to-
charge ratio for the discrete peptide ions in each sample. MS/MS
spectra that were simultaneously acquired were used to provide
amino acid sequence information for selected peptide ions.
Data analysis
Acquired MS data were uploaded to the Elucidator data
analysis system (Rosetta Biosoftware, version 3.5) as previously
described [5,43] for feature extraction, quantitative analysis and
searched against a human PDK1 database obtained from National
Center for Biotechnology Information (NCBI) http://pubchem.
ncbi.nlm.nih.gov/ using SEQUEST. Parameters for the searches
included the following: Trypsin, AspN, GluC for enzyme
specificity respectively; static modifications of 57.02 Da on Cys
Figure 5. The pharmacological biomarker audit trail. Biomarker categories demonstrate the relationship between the specificity of target
engagement biomarkers (i.e. proximal biomarkers) and distal disease-related outcome biomarkers. Direct target engagement markers allow lead
optimization of compounds at the kinase target level.
doi:10.1371/journal.pone.0026459.g005
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Ser, Thr, and Tyr (phosphorylation) and 15.99 Da on Met
(oxidation). The precursor ion mass tolerance was set as 50 ppm
and the fragment-ion mass tolerance was set as +/20.8 Da
Mono/Mono. Each MS/MS spectra exhibiting possible phos-
phorylation were manually validated. ‘Light’ and ‘heavy’ SILAC
labeled peptide pairs are identified based on m/z and the retention
time of the features contained in the data set. The ratio of the
identified peptide pairs were then derived based on the ratio of
their corresponding areas under the ion chromatographic curves.
Supporting Information
Figure S1 Relative quantification of MARK3 phosphor-
ylation by SILAC-IAP-MS. A) MARK3 targeting inhibitors. B)
Relative quantification by SILAC-IAP-MS showed the signal
intensity of three phosphorylation sites (pS469, pS390/391 and
pS400) were dose-dependently reduced in response to both
inhibitor 5 and 6.
(TIF)
Figure S2 Relative quantification of c-Met phosphory-
lation by SILAC-IAP-MS. A) Fold changes for c-Met
phosphopeptides treated with MK-2461 treatment vs. DMSO
(red columns) were obtained as described in materials and
methods. B) Reconstructed ion chromatogram and C) high
resolution full MS spectra of both light (black) and heavy (red)
peptides ISAIFSTFIGEHpYVHVNATpYVNVK (Y1349/
Y1356) respectively.
(TIF)
Table S1 Relative quantification of c-Met phosphoryla-
tion by SILAC-IAP-MS. DMSO and IC90 refer to treating cells
either using DMSO or MK-2461 at IC90 concentration, (L) and
(H) refer to light and heavy isotope media.
(DOC)
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